Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
Kiniksa reported Q1 2026 revenue of $214.3 million, a 56% increase year-over-year, driven by strong adoption of ARCALYST for recurrent pericarditis and expanding prescriber base. Following the robust performance, the company raised its full-year 2026 ARCALYST net sales guidance to between $930 million and $945 million, up from the prior range of $900 million to $920 million.
Key figures
- Eps
- 0.27
- Revenue
- 214300000
- Guidance
- 2026 ARCALYST net product revenue $930 - $945 million, raised from $900 - $920 million
- Revenue Yoy
- 56%
- Cash Balance
- 468100000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.